Small nuclear ribonucleoproteins: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
mNo edit summary |
||
| Line 16: | Line 16: | ||
| url = http://emedicine.medscape.com/article/335815-overview}}</ref> | | url = http://emedicine.medscape.com/article/335815-overview}}</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}}[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 06:01, 19 October 2024
Small nuclear ribonucleoproteins are highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm, and pre-rRNA processing in the nucleolus[1] Antibodies to these proteins may be clinically significant in a number of rheumatological diseases.
"Systemic lupus erythematosus is characterized by production of autoantibodies to RNA or DNA–protein complexes such as small nuclear ribonucleoproteins (snRNPs). A role of Epstein–Barr virus in the pathogenesis has been suggested. Similar to Epstein–Barr virus, cytomegalovirus (CMV) infects the majority of individuals at a young age and establishes latency with a potential for reactivation...CMV [may have a role] in regulation of autoantibodies to snRNPs" [2]
Antibodies against the subclass U1 small nuclear ribonucleoproteins (anti-U1 snRNP OR anti-U1 RNP) are characteristic of mixed connective tissue disease.[3]
References
- ↑ Anonymous (2024), Small nuclear ribonucleoproteins (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Claudia Azucena Palafox Sánchez et al. (2009), "Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies", Arthritis Research & Therapy 11: R27, DOI:10.1186/ar2621
- ↑ Robert W Hoffman and Eric L Greidinger (7 August 2008), "Mixed Connective-Tissue Disease: Overview", eMedicine Specialties > Rheumatology > Systemic Rheumatic Disease